6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-26), Sage Therapeutics's 6-1 Month Momentum % is 2.13%.
The industry rank for Sage Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
SAGE's 6-1 Month Momentum % is ranked worse than 51.55% of 1521
companies
in the Biotechnology industry
Industry Median: 4.08
vs SAGE: 2.13
Competitive Comparison of Sage Therapeutics's 6-1 Month Momentum %
For the Biotechnology subindustry, Sage Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sage Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sage Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Sage Therapeutics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Sage Therapeutics 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Sage Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sage Therapeutics (Sage Therapeutics) Business Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SAGE has been successfully added to your